Sunshin Kim

VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR‐Tyrosine Kinase Inhibitor‐Resistant Non‐Small Cell Lung Cancer

Se Hwa Hong, Namhee Yu, Ju Young Cho, Geon Kook Lee et autres

ABSTRACT Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) therapy is beneficial for epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI)‐resistant non‐small cell lung cancer (NSCLC); however, the resistance mechanisms are not fully understood. In this study, we conducted a single‐cell RNA‐sequencing analysis of EGFR‐TKI‐resistant …

us, kr (code pays fourni par la source)

Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition

Yura Choi, Mihwa Hwang, Jae Min Kim, Seog Yun Park et autres

MET-targeted therapies are the most effective treatment for patients with MET-amplified lung cancer. However, acquired drug resistance is a significant challenge in MET-amplified lung cancer treatment. This study aimed to discover an effective treatment strategy for overcoming MET-targeted drug resistance. We first …

us, kr (code pays fourni par la source)

Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer

Yura Choi, Eun Hye Kang, Sunshin Kim, Seog‐Yun Park et autres

kr, us (code pays fourni par la source)

Abstract 2805: Pharmacogenomic platform using patient-derived cells to delineate tumor heterogeneity and therapeutic response of refractory lung cancer

Charny Park, Se Hwa Hong, Mihwa Hwang, Youngjoo Lee et autres

Abstract A pharmacogenomic platform using patient-derived cells (PDCs) was established to identify the underlying resistance mechanisms and tailored treatment for advanced or refractory lung cancer patients. Drug sensitivity screening was acquired from short-term PDC culture and multi-omics datasets were acquired from lung …

us (code pays fourni par la source)

Abstract 4929: ICX-101, a novel MYC inhibitor, shows antitumor activity in patient-derived cells of advanced lung cancer with high MYC expression

Wonyoung Choi, Kyung‐Chae Jeong, Seog-Yun Park, Sunshin Kim et autres

Abstract Background: MYC is an attractive therapeutic target in lung cancer. ICX-101 is a novel potent, selective small molecule that directly inhibits the binding of MYC/MAX dimers to the DNA binding sequence E-box. Here, we show that ICX-101 shows antitumor activity in …

kr (code pays fourni par la source)

Abstract 2806: Patient-derived cell-based pharmacogenomic platform to uncover resistance mechanisms and novel therapeutics for advanced lung cancer

Charny Park, Namhee Yu, Mihwa Hwang, Youngjoo Lee et autres

Abstract To uncover resistance mechanism and effective drugs for advanced lung cancer patients, we stablished a pharmacogenomic platform using patient-derived cells (PDC). Drug response screening and multi-omics datasets were obtained from lung cancer PDCs (n=102). We interrogated sensitive drugs from variant, gene …

us (code pays fourni par la source)

Abstract 6217: Inhibiting ataxia-telangiectasia mutated and RAD3-related (ATR) by BAY 1895344 overcomes chemoresistance to oxaliplatin and promotes synergistic anti-tumor effect in pancreatic cancer

Hye Won Shon, Jung Won Chun, Jeong Eun Gong, Mi Rim Lee et autres

Abstract Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease with a poor prognosis and a limited response to most of the treatments. Despite a platinum-based drug such as oxaliplatin or cisplatin is one of the most effective chemotherapy drugs for PDAC, …

kr (code pays fourni par la source)

Abstract 417: Targeting aurora kinase b overcomes acquired resistance to met-tyrosine kinase inhibitor in met-amplified lung cancer

Yura Choi, Mihwa Hwang, Sunshin Kim, Jae J. Song et autres

Abstract Mesenchymal-epithelial transition factor receptor (MET) mediated signaling emerged as an important clinical target for the treatment of many cancer types including non-small cell lung cancer. MET amplification is prevalent in 2%~4% of primary lung cancer and 15%~50% of EGFR-mutated lung cancer …

kr (code pays fourni par la source)

Ataxia-Telangiectasia Mutated Is Involved in Autolysosome Formation

Mihwa Hwang, Dong Wha Jun, Bo Song, Hanna Shim et autres

Ataxia-telangiectasia mutated (ATM), a master kinase of the DNA damage response (DDR), phosphorylates a multitude of substrates to activate signaling pathways after DNA double-strand breaks (DSBs). ATM inhibitors have been evaluated as anticancer drugs to potentiate the cytotoxicity of DNA damage-based cancer …

kr (code pays fourni par la source)

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

Namhee Yu, Mihwa Hwang, Youngjoo Lee, Bo Song et autres

BACKGROUND: A pharmacogenomic platform using patient-derived cells (PDCs) was established to identify the underlying resistance mechanisms and tailored treatment for patients with advanced or refractory lung cancer. METHODS: Drug sensitivity screening and multi-omics datasets were acquired from lung cancer PDCs (n = …

kr (code pays fourni par la source)

Additional file 2 of Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

Namhee Yu, Mihwa Hwang, Youngjoo Lee, Bo Song et autres

Additional file 2: Table S1. Clinical information and molecular subtypes of 102 lung cancer patients used to obtain PDCs. Table S2. The 48 drugs employed in the screening panel. We refer to the chemical or generic name of the drugs, and the …

kr (code pays fourni par la source)

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

Namhee Yu, Mihwa Hwang, Youngjoo Lee, Bo Song et autres

us, kr (code pays fourni par la source)